
Dr. Patrick Walsh Explains: FDA Advisory Panel Rejects Proscar and Avodart to Reduce Risk of Prostate Cancer
In December, 2010 an FDA advisory panel met to evaluate two proposals for the use of 5a reductase inhibitors to reduce the risk of prostate cancer. The panel rejected both voting 17-0 with one abstention that the risks of Proscar…